A recent pharmaceutical patent case in India has highlighted the strict requirements for disclosure to the Indian Patent Office. In this case, Allergan had its patent for a combination ophthalmic therapy using Brimonidine and Timolol invalidated as failing to comply with the disclosure requirements of Section 8 of the Indian Patent Act. Section 8 requires … Continue Reading